Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease
References (31)
- et al.
Isolation of MAP from breast milk of Crohn's disease patients
Am J Gastroenterol
(2000) - et al.
Antimycobacterial therapy ineffective in Crohn's disease after a year
Lancet
(1989) - et al.
Treatment of severe Crohn's disease (CD) using rifabutin-macrolide-clofazimine combination; iterim report
Gastroenterology
(1998) - et al.
Development of a Crohn's disease activity index
Gastroenterology
(1976) Chronic intestinal enteritis
Br Med J
(1913)- et al.
Medical therapy of active Crohn's disease
Bailliere's Clin Gastroenterol
(1998) Current concepts in pathogenesis of Crohn's disease
J Gastroenterol Hepatol
(1990)- et al.
Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease
Dig Dis Sci
(2000) - et al.
Characteristics of an unclassified mycobacterium species isolated from patients with Crohn's disease
J Clin Microbiol
(1984) - et al.
Crohn's disease isolated mycobacteria are identical to MAP as determined by DNA probes that distinguish mycobacterial species
J Clin Microbiol
(1987)
MAP DNA in Crohn's disease tissue
Gut
(1992)
PCR detection of Mycobacterium Paratuberculosis in long-term cultures from Crohn's disease tissues
Gut
(1992)
MAP in Crohn's disease is serologically positive
Clin Diagn Lab Immunol
(1999)
Screening of a MAP expression library with polyclonal antiserum and amplified DNA probes to identify species-specific immunodominant antigens
Use of short-term culture for the identification of Mycobacterium avium subs. Paratuberculosis in tissue from Crohn's disease patients
Clin Microbiol Infect
(2000)
Cited by (96)
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
2015, Pharmacology and TherapeuticsCitation Excerpt :In a small open-label trial, rifabutin and clarithromycin were tested also in association with probiotic supplementation (various Lactobacilli and Bifidobacteria) to achieve remission in active CD patients. About 60% of patients experienced a sustained reduction in CDAI Score (Shafran et al., 2002). An early Cochrane Database Review (Borgaonkar et al., 2000) stated that anti-mycobacterials may play a role in the maintenance of remission when it has been achieved through combination of them with corticosteroids.
Pathogens in Crohn’s Disease: The Role of Adherent Invasive Escherichia coli
2024, Critical Reviews in Eukaryotic Gene ExpressionAntibiotic therapy
2023, Pediatric Inflammatory Bowel DiseaseECCO Topical Review: Refractory Inflammatory Bowel Disease
2021, Journal of Crohn's and ColitisAnti-Mycobacterium paratuberculosis (MAP) therapy for Crohn's disease: An overview and update
2021, Frontline Gastroenterology
Copyright © 2002 Published by Elsevier Ltd.